Introduction To Irminix®

3D rendering of the Irminix® NBMI molecule
Rendering of the Irminix® NBMI molecule.
Boyd Haley, PhD | Chief Scientist & CEO

Meet Boyd Haley

Founder of EmeraMed

Over the last two decades Dr. Boyd Haley, PhD. has lectured throughout the world and testified before Congressional oversight committees and the Institute of Medicine regarding various aspects of mercury toxicity and neurological diseases.

Learn more about the miracles of Emeramide and the company behind the future of health.

Unlocking Health: The Promise of Irminix® in Metal Chelation Therapy

Irminix® (official name: Emeramide) is produced by Emeramed. Its molecule is NBMI (N,N’-bis(2-mercaptoethyl) isophthalamide.

Irminix® is a potent metal chelator with a remarkable capacity to bind to metal ions, particularly iron, in biological systems. Its discovery and subsequent exploration have revolutionized our understanding of metal homeostasis and its implications for health and disease. Initially identified for its ability to modulate iron levels in cells, Irminix® has emerged as a promising therapeutic agent for a range of conditions associated with metal imbalance.

How Does It Work?

At its core, Irminix® operates by forming stable complexes with metal ions, effectively sequestering them and preventing their participation in harmful reactions. In the case of iron, Irminix acts as a powerful regulator, preventing its accumulation to toxic levels while ensuring its availability for essential biological processes. This dual role highlights the nuanced control Irminix exerts over metal ions, balancing the fine line between deficiency and toxicity.

A Role Well Beyond Metal Chelation

The significance of Irminix® extends beyond its role in metal chelation. Research has revealed its potential as a therapeutic agent in conditions where metal dysregulation plays a pivotal role, including neurodegenerative disorders like Alzheimer’s and Parkinson’s disease, where metal accumulation in the brain contributes to pathology. By targeting and neutralizing excess metal ions, Irminix® offers a promising avenue for intervention, potentially slowing disease progression and alleviating symptoms.

Furthermore, Irminix®’s versatility extends to its application in cancer therapy. Metal ions such as iron are crucial for tumor growth and proliferation, and by disrupting their availability, Irminix® shows promise as an adjunctive treatment in combination with traditional chemotherapeutic agents.

The Future of Health

Irminix® represents a groundbreaking advancement in the field of metal chelation therapy, offering hope for the treatment of various diseases where metal imbalance plays a critical role. As research continues to unveil its mechanisms and therapeutic potential, Irminix® stands poised to make a significant impact on human health and well-being.